Care pathway of patients with hepatocellular carcinoma in France: State of play in 2017

被引：1
作者：
Costentin, Charlotte [1 ]
Ganne-Carrie, Nathalie [2 ]
Rousseau, Benoit [3 ]
Gerolami, Rene [4 ]
Barbare, Jean-Claude [5 ]
机构：
[1] Hop Henri Mondor, AP HP, Serv Hepatol, 51 Ave Marechal De Lattre De Tassigny, F-94000 Creteil, France
[2] Hop Jean Verdier, AP HP, Serv Hepatol, Ave 14 Juillet, F-93140 Bondy, France
[3] Hop Henri Mondor, AP HP, Inst Mondor Rech Biomed, Serv Oncol Med,INSERM,U955,Equipe 18, 51 Ave Marechal De Lattre De Tassigny, F-94000 Creteil, France
[4] Hop La Timone, Serv Hepatogastroenterol, 264 Rue St Pierre, F-13385 Marseille, France
[5] CHU Amiens, Delegat Rech Clin & Innovat, Site Sud, F-80054 Amiens 1, France
来源：
BULLETIN DU CANCER | 2017年 / 104卷 / 09期
关键词：
Hepatocellular carcinoma; Care pathway; Screening; Delays in management; Pathways of improvement; CLINICAL-PRACTICE; SURVEILLANCE; CIRRHOSIS; SURVIVAL; MANAGEMENT; THERAPY; COHORT; LIVER; RISK; DIAGNOSIS;
D O I：
10.1016/j.bulcan.2017.06.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Hepatocellular carcinoma is a major public health problem with one of the highest overall mortality compared to other cancers. The median overall survival in France in a hospital population with hepatocellular carcinoma is 9.4 months. Several publications reported a positive impact of hepatocellular carcinoma screening on diagnosis at an early-stage, eligibility for curative treatment and overall survival. However, the identification of patients to be included in a hepatocellular carcinoma screening program and the application of screening recommendations ore not optimal. Other studies suggest a potentially negative impact of delayed diagnosis or treatment initiation on the patient's prognosis. Finally, marked variations between French regions and departments have been described in terms of access to curative treatment and overall survival. In this review article, we propose a state of play of the hepatocellular carcinoma patient's care pathway in France with the aim of identifying potential breaking points with negative impact on prognosis and of developing proposals for improvement.
引用
收藏
页码：752 / 761
页数：10
相关论文
共 45 条
[1]  
[Anonymous], 2013, SURVIE PERSONNES ATT
[2]   Should cases of hepatocellular carcinoma be discussed by non-specialized multidisciplinary team meetings? [J].
Barbare, Jean-Claude ;
Franco, Dominique ;
Andre, Thierry ;
Bronowicki, Jean-Pierre ;
Merle, Philippe ;
Peron, Jean-Marie ;
Raoul, Jean-Luc ;
Seitz, Jean-Francois ;
Ychou, Marc .
BULLETIN DU CANCER, 2014, 101 (06) :558-563
[3]   EFFECTIVENESS AND SAFETY OF BACLOFEN TREATMENT IN ALCOHOL-DEPENDENT PATIENTS WITH OR WITHOUT LIVER CIRRHOSIS: RESULTS OF AN OPEN STUDY IN TRUE LIFE [J].
Barrault, C. ;
Lison, H. ;
Sarlon, E. ;
Cordonnier, M. ;
Rosa, I. ;
Belloula, D. ;
Pulwermacher, G. ;
Hagege, H. ;
Cadranel, J. -F. .
JOURNAL OF HEPATOLOGY, 2013, 58 :S212-S212
[4]   The Undiagnosed Chronically-Infected HCV Population in France. Implications for Expanded Testing Recommendations in 2014 [J].
Brouard, Cecile ;
Le Strat, Yann ;
Larsen, Christine ;
Jauffret-Roustide, Marie ;
Lot, Florence ;
Pillonel, Josiane .
PLOS ONE, 2015, 10 (05)
[5]   Implementation of a nurse-driven educational program improves management of sorafenib's toxicities in hepatocellular carcinoma [J].
Brunot, Angelique ;
M'Sadek, Amel ;
Le Roy, Florence ;
Duval, Marielle ;
Le Sourd, Samuel ;
Ventroux, Elodie ;
Crouzet, Laurence ;
Guillygomarc'h, Anne ;
Boucher, Eveline ;
Lelievre, Nadine ;
Laguerre, Brigitte ;
Edeline, Julien .
BULLETIN DU CANCER, 2016, 103 (11) :941-948
[6]   Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome [J].
Bucci, L. ;
Garuti, F. ;
Camelli, V. ;
Lenzi, B. ;
Farinati, F. ;
Giannini, E. G. ;
Ciccarese, F. ;
Piscaglia, F. ;
Rapaccini, G. L. ;
Di Marco, M. ;
Caturelli, E. ;
Zoli, M. ;
Borzio, F. ;
Sacco, R. ;
Maida, M. ;
Felder, M. ;
Morisco, F. ;
Gasbarrini, A. ;
Gemini, S. ;
Foschi, F. G. ;
Missale, G. ;
Masotto, A. ;
Affronti, A. ;
Bernardi, M. ;
Trevisani, F. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (03) :385-399
[7]   Early Detection and Curative Treatment of Hepatocellular Carcinoma: A Cost-Effectiveness Analysis in France and in the United States [J].
Cadier, Benjamin ;
Bulsei, Julie ;
Nahon, Pierre ;
Seror, Olivier ;
Laurent, Alexis ;
Rosa, Isabelle ;
Layese, Richard ;
Costentin, Charlotte ;
Cagnot, Carole ;
Durand-Zaleski, Isabelle ;
Chevreul, Karine .
HEPATOLOGY, 2017, 65 (04) :1237-1248
[8]  
Costentin C, 2016, COMPLIANCE HEPATOCEL
[9]   Referral and Receipt of Treatment for Hepatocellular Carcinoma in United States Veterans: Effect of Patient and Nonpatient Factors [J].
Davila, Jessica A. ;
Kramer, Jennifer R. ;
Duan, Zhigang ;
Richardson, Peter A. ;
Tyson, Gia L. ;
Sada, Yvonne H. ;
Kanwal, Fasiha ;
El-Serag, Hashem B. .
HEPATOLOGY, 2013, 57 (05) :1858-1868
[10]   Utilization and Outcomes of Palliative Therapy for Hepatocellular Carcinoma A Population-based Study in the United States [J].
Davila, Jessica A. ;
Duan, Zhigang ;
McGlynn, Katherine A. ;
El-Serag, Hashem B. .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2012, 46 (01) :71-77
12345